Mesoblast Limited (AU:MSB) has released an update.
Mesoblast Limited, a leader in allogeneic cellular medicines, has announced plans to submit a Biologics License Application for Ryoncil to the FDA to treat children with a severe inflammatory condition. The treatment targets steroid-refractory acute graft versus host disease, showcasing the company’s commitment to innovative cellular therapies. Mesoblast’s broad portfolio and global intellectual property are set to deliver off-the-shelf remedies for life-threatening inflammatory diseases, with a reach extending through at least 2041.
For further insights into AU:MSB stock, check out TipRanks’ Stock Analysis page.
